Vimarsana
Biggest News Aggregation in the World

Page 38 - Priya Singhal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Priya Singhal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Priya Singhal Today - Breaking & Trending Today

Injected version of Eisai/Biogen Alzheimer's drug effective | The Asahi Shimbun: Breaking News, Japan News and Analysis - Vimarsana News

Injected version of Eisai/Biogen Alzheimer's drug effective | The Asahi Shimbun: Breaking News, Japan News and Analysis

BOSTON--An injected version of Eisai and Biogen's Alzheimer's drug Leqembi works as well as the current intravenous administration at removing toxic brain plaques, but rates of serious side effects were higher, according to an analysis presented by Eisai on Wednesday.

Source: asahi.com
Biogen Inc. (NASDAQ:BIIB) Holdings Raised by Picton Mahoney Asset Management - Vimarsana News

Biogen Inc. (NASDAQ:BIIB) Holdings Raised by Picton Mahoney Asset Management

Picton Mahoney Asset Management grew its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 5.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,202 shares of the biotechnology company’s stock after acquiring an additional 959 shares during the quarter. Picton Mahoney Asset […]

Alzheimer's: Biogen and Eli Lilly present clinical treatment data - Vimarsana News

Alzheimer's: Biogen and Eli Lilly present clinical treatment data

Cambridge-based Biogen is vying with the pharmaceutical giant Eli Lilly for leadership in the emerging multibillion-dollar market for Alzheimer’s therapies.

New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease -October 25, 2023 at 10:52 am EDT - Vimarsana News

New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease -October 25, 2023 at 10:52 am EDT

In the Phase 1b study, favorable trends were reported for the high-dose groups on multiple measures of cognition and function.First study of a tau targeting drug that shows reduction of aggregated tau...

New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease -October 25, 2023 at 10:51 am EDT - Vimarsana News

New Data from Biogen's Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer's Disease -October 25, 2023 at 10:51 am EDT

In the Phase 1b study, favorable trends were reported for the high-dose groups on multiple measures of cognition and function.First study of a tau targeting drug that shows reduction of aggregated tau...